Multivariate analysis indicated that ABCC2 c.3972C > T is a risk factor for the occurrence of grade 1–4 neutropenia at the first cycle in patients who receive irinotecan-based chemotherapy. This evidence concerns the gene ABCC2 and neutropenia.